Airway hypersecretion in allergic rhinitis and asthma: New pharmacotherapy

Current Allergy and Asthma Reports

Volumn 3, Issue 3, 2003, Pages 238-248

  Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTISENSE OLIGONUCLEOTIDE; APAFANT; BATIMASTAT; BOSENTAN; CHLORIDE CHANNEL; CICLESONIDE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DESLORATADINE; EBASTINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE; GEFITINIB; GLUCOCORTICOID; HISTAMINE; ICATIBANT; INDOMETACIN; MOMETASONE FUROATE; MONTELUKAST; ODN 64; ODN 83; PROTEIN BCL 2; TIPREDANE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST; ANTIHISTAMINIC AGENT;

AIRWAY; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CELL SECRETION; DRUG TARGETING; HUMAN; INFLAMMATORY CELL; MEDIATOR RELEASE; MUCUS SECRETION; NONHUMAN; PHENOTYPE; REVIEW; SIDE EFFECT; CAPILLARY PERMEABILITY; DRUG ANTAGONISM; HAY FEVER; METABOLISM; MUCUS; NOSE MUCOSA; PERENNIAL RHINITIS; SECRETION;

ASTHMA; CAPILLARY PERMEABILITY; CHLORIDE CHANNELS; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; MUCUS; NASAL MUCOSA; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0038659352     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-003-0046-1     Document Type: Review

References (75)

1. Ferguson BJ: Allergic rhinitis: recognizing signs, symptoms, and triggering allergens. Postgrad Med 1997, 101:110-116.
2. Liu YC, Khawaja AM, Rogers DF: Pathophysiogy of airway mucus secretion in asthma. In Asthma: Basic Mechanisms and Clinical Management, 3rd edn. Edited by Barnes PJ, Rodger IW, Thomson NC. London: Academic Press; 1998:205-227.
3. Passalacqua G, Ciprandi G, Canonica GW: The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol 2001, 1:7-13.
4. Knowles MR, Boucher RC: Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002, 109:571-577.
5. Davies JR, Herrmann A, Russell W, et al.: Respiratory tract mucins: structure and expression patterns. In Mucus Hypersecretion in Respiratory Disease. Novartis Symposium Foundation 248, Chichester: John Wiley & Sons; 2002:76-88.
6. Dekker J, Rossen JW, Buller HA, Einerhand AW: The MUC family: an obituary. Trends Biochem Sci 2002, 27:126-131.
7. Howarth PH, Salagean M, Dokic D: Allergic rhinitis: not purely a histamine-related disease. Allergy 2000, 55(Suppl 64):7-16.
8. Mygind N: Nasal inflammation and anti-inflammatory treatment: semantics or clinical reality. Rhinology 2001, 39:61-65.
9. Tai CF, Baraniuk JN: Upper airway neurogenic mechanisms. Curr Opin Allergy Clin Immunol 2002, 2:11-19.
10. Pelikan Z, Pelikan-Filipek M: Immediate nasal response to allergen challenge cytologic changes in the nasal secretions and histologic changes in the nasal mucosa. Adv Exp Med Biol 1995, 371B:847-853.
11. Pelikan Z, Pelikan-Filipek M: Late nasal response to allergen challenge cytologic changes in the nasal secretions and histologic changes in the nasal mucosa. Adv Exp Med Biol 1995, 371B:855-860.
12. Gluck U, Gebbers J: Epithelial changes in seasonal allergic rhinitis throughout the year: evidence of coexistent air pollution and local secretory IgA deficiency? ORL J Otorhinolaryngol Relat Spec 2000, 62:68-75.
13. Bavbek S, Sencer H, Misirligil Z, et al.: Light and electron microscope study in allergic rhinitis patients (ARP) with or without bronchial hyperreactivity (BHR). J Investig Allergol Clin Immunol 1996, 6:172-182.
14. Berger G, Marom Z, Ophir D: Goblet cell density of the inferior turbinates in patients with perennial allergic and nonallergic rhinitis. Am J Rhinol 1997, 11:233-236.
15. Karlsson G, Pipkorn U: Natural allergen exposure does not influence the density of goblet cells in the nasal mucosa of patients with seasonal allergic rhinitis. Otorhinolaryngol Relat Spec 1989, 51:171-174.
16. Berger G, Moroz A, Marom Z, Ophir D: Inferior turbinate goblet cell secretion in patients with perennial allergic and non-allergic rhinitis. Am J Rhinol 1999, 13:473-477.
17. Toppozada HH, Talaat MA: Tunica propria in chronic allergic rhinitis. Electron-microscopic study. I. The nasal blood vessels. J Otorhinolaryngol Relat Spec 1976, 38:86-92.
18. Mir-Salim PA, Merker HJ, Jahnke V, Berghaus A: [Glands of the human nasal mucosa - electron microscopy and immunohistochemical studies]. Laryngorhinootologie 1998, 77:322-327.
19. Toppozada HH, Gaafar HA: Electron microscopy of the human nasal mixed glands. J Laryngol Otol 1973, 87:639-645.
20. Takeuchi K, Yuta A, Sakakura Y: MUC2 mucin gene expression in the nose and maxillary sinus. Am J Otolaryngol 1995, 16:391-395.
21. Voynow JA, Selby DM, Rose MC: Mucin gene expression (MUC1, MUC2, and MUC5/5AC) in nasal epithelial cells of cystic fibrosis, allergic rhinitis, and normal individuals. Lung 1998, 176:345-354.
22. Wood SJ, Birchall MA, Carlstedt I, Corfield AP: The expression of MUC5AC in allergic rhinitis. Biochem Soc Trans 1997, 25:504S.
23. National Institutes of Health: Global Initiative for Asthma: pocket guide for asthma management and prevention. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002: Publication no. 02-3659.
24. Eapen SS, Busse WW: Asthma. Clin Allergy Immunol 2002, 16:325-353.
25. Rogers DF, Evans TW: Plasma exudation and oedema in asthma. Br Med Bull 1992, 48:120-134.
26. Rogers DF: Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis 2000, 55:324-332.
27. Kirkham S, Sheehan JK, Knight D, et al.: Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002, 361:537-546.
28. Aust MR, Madsen CS, Jennings A, et al.: Mucin mRNA expression in normal and vasomotor inferior turbinates. Am J Rhinol 1997, 11:293-302.
29. Rogers DF: Mucoactive drugs for asthma and COPD: Any place in therapy? Expert Opin Investig Drugs 2002, 11:15-35.
30. Holm AF, Fokkens WJ: Topical corticosteroids in allergic rhinitis; effects on nasal inflammatory cells and nasal mucosa. Clin Exp Allergy 2001, 31:529-535.
31. Dent G: Ciclesonide (Byk Gulden). Curr Opin Investig Drugs 2002, 3:78-83.
32. Greiff L, Persson CG, Andersson M: Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol 2002, 89:413-418.
33. Amichai B, Grunwald MH, Brenner L: Fexofenadine hydrochloride: a new anti-histaminic drug. Isr Med Assoc J 2001, 3:207-209.
34. Kingham P: Carebastine Almirall Prodesfarma. Curr Opin Investig Drugs 2000, 1:90-96.
35. Borish L: The role of leukotrienes in upper and lower air-way inflammation and the implications for treatment. Ann Allergy Asthma Immunol 2002, 88:16-22.
36. Liu YC, Khawaja AM, Rogers DF: Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea pigs in vitro. Br J Pharmacol 1998, 124:563-571.
37. Shirasaki H, Kanaizumi E, Watanabe K, et al.: Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002, 32:1007-1012.
38. Storms WW: Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 2002, 88:30-35.
39. Rogers DF: Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002, 2:249-255.
40. Mullol J, Baraniuk JN, Logun C, et al.: M1 and M3 muscarinic antagonists inhibit human nasal glandular secretion in vitro. J Appl Physiol 1992, 73:2069-2073.
41. Ramnarine SI, Haddad EB, Khawaja AM, et al.: On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol 1996, 494:577-586.
42. Nakaya M, Yuasa T, Usui N: Immunohistochemical localization of subtypes of muscarinic receptors in human inferior turbinate mucosa. Ann Otol Rhinol Laryngol 2002, 111:593-597.
43. Pavia D, Sutton PP, Lopez-Vidriero MT, et al.: Drug effects on mucociliary function. Eur J Respir Dis Suppl 1983, 128:304-317.
44. Hvizdos KM, Goa KL: Tiotropium bromide. Drugs 2002, 62:1195-1203.
45. Rubin BK: The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002, 47:818-822.
46. Poole PJ, Black PN: Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001, 322:1271-1274.
47. Wright DT, Fischer BM, Li C, et al.: Oxidant stress stimulates mucin secretion and PLC in airway epithelium via a nitric oxide-dependent mechanism. Am J Physiol 1996, 271:L854-L861.
48. Rogers DF: Tachykinin receptor antagonists for asthma and COPD. Expert Opin Ther Patents 2001, 11:1097-1121.
49. Spicuzza L, Haddad EB, Birrell M, et al.: Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. Br J Pharmacol 2000, 130:1720-1726.
50. Caterina MJ, Julius D: The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001, 24:487-517.
51. Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol 2001, 63:569-611.
52. Wills-Karp M: Trophic slime, allergic slime. Am J Respir Cell Mol Biol 2000, 22:637-639.
53. Levine SJ, Larivee P, Logun C, et al.: Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Mol Biol 1995, 12:196-204.
54. Shim JJ, Dabbagh K, Takeyama K, et al.: Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol 2000, 105:739-745.
55. Kanehiro A, Ikemura T, Makela MJ, et al.: Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001, 163:173-184.
56. Schmidt BM, Kusma M, Feuring M, et al.: The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001, 108:530-536.
57. Li Y, Martin LD, Spizz G, Adler KB: MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro. J Biol Chem 2001, 276:40982-40990.
58. Lee HM, Malm L, Dabbagh K, et al.: Epidermal growth factor receptor signaling mediates regranulation of rat nasal goblet cells. J Allergy Clin Immunol 2001, 107:1046-1050.
59. Nadel JA, Burgel PR: The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001, 1:254-258.
60. Sommerhoff CP, Caughey GH, Finkbeiner WE, et al.: Mast cell chymase: a potent secretagogue for airway gland serous cells. J Immunol 1989, 142:2450-2456.
61. Clark JM, Abraham WM, Fishman CE, et al.: Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. Am J Respir Crit Care Med 1995, 152:2076-2083.
62. Woodruff PG, Fahy JV: A role for neutrophils in asthma? Am J Med 2002, 112:498-500.
63. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH: Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990, 85:682-689.
64. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al.: Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999, 20:729-736.
65. Nadel JA, Takeyama K, Agusti C: Role of neutrophil elastase in hypersecretion in asthma. Eur Respir J 1999, 13:190-196.
66. Nogami H, Aizawa H, Matsumoto K, et al.: Neutrophil elastase inhibitor, ONO-5046 suppresses ozone-induced airway mucus hypersecretion in guinea pigs. Eur J Pharmacol 2000, 390:197-202.
67. Kellerman DJ: P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest 2002, 121(5 Suppl):201S-205S.
68. Goswami SK, Kivity S, Marom Z: Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990, 141:72-78.
69. Wales D, Woodhead M: The anti-inflammatory effects of macrolides. Thorax 1999, 54(Suppl 2):S58-S62.
70. Gorrini M, Lupi A, Viglio S, et al.: Inhibition of human neutrophil elastase by erythromycin and flurithromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001, 25:492-499.
71. Wang B, Lim DJ, Flan J, et al.: Novel cytoplasmic proteins of non-typeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway. J Biol Chem 2002, 277:949-957.
72. Nakanishi A, Morita S, Iwashita H, et al.: Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci U S A 2001, 98:5175-5180.
73. Toda M, Tulic MK, Levitt RC, Hamid Q: A calcium-activated chloride channel (HCLCA1) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 2002, 109:246-250.
74. Tesfaigzi Y, Fischer MJ, Martin AJ, Seagrave J: Bcl-2 in LPS- and allergen-induced hyperplastic mucous cells in airway epithelia of Brown Norway rats. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1210-L1217.
75. Bhattacharyya SN, Manna B, Smiley R, et al.: Smoke-induced inhalation injury: effects of retinoic acid and antisense oligodeoxynucleotide on stability and differentiated state of the mucociliary epithelium. Inflammation 1998, 22:203-214.